학술논문

발행년
-
(예 : 2010-2015)
'학술논문' 에서 검색결과 12건 | 목록 1~10
Academic Journal
Calviño C; Hematology and Cell Therapy Department, Clinica Universidad de Navarra, IdiSNA, Pamplona, Spain.; Ceballos C; Hematology Department, Hospital Universitario de Navarra, IdiSNA, Pamplona, Spain.; Alfonso A; Hematology and Cell Therapy Department, Clinica Universidad de Navarra, IdiSNA, Pamplona, Spain.; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain.; Jauregui P; Hematology and Cell Therapy Department, Clinica Universidad de Navarra, IdiSNA, Pamplona, Spain.; Calleja-Cervantes ME; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Computational Biology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; San Martin-Uriz P; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Rodriguez-Marquez P; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain.; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Martin-Mallo A; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Iglesias E; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Abizanda G; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Rodriguez-Diaz S; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Martinez-Turrillas R; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain.; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Illarramendi J; Hematology Department, Hospital Universitario de Navarra, IdiSNA, Pamplona, Spain.; Viguria MC; Hematology Department, Hospital Universitario de Navarra, IdiSNA, Pamplona, Spain.; Redondo M; Hematology Department, Hospital Universitario de Navarra, IdiSNA, Pamplona, Spain.; Rifon J; Hematology and Cell Therapy Department, Clinica Universidad de Navarra, IdiSNA, Pamplona, Spain.; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain.; Villar S; Hematology and Cell Therapy Department, Clinica Universidad de Navarra, IdiSNA, Pamplona, Spain.; Lasarte JJ; Immunology and Immunotherapy Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain.; Inoges S; Hematology and Cell Therapy Department, Clinica Universidad de Navarra, IdiSNA, Pamplona, Spain.; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain.; Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain.; Immunology and Immunotherapy Department, Clinica Universidad de Navarra, Pamplona, Spain.; Lopez-Diaz de Cerio A; Hematology and Cell Therapy Department, Clinica Universidad de Navarra, IdiSNA, Pamplona, Spain.; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain.; Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain.; Immunology and Immunotherapy Department, Clinica Universidad de Navarra, Pamplona, Spain.; Hernaez M; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain.; Computational Biology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain.; Data Science and Artificial Intelligence Institute (DATAI), Universidad de Navarra, Pamplona, Spain.; Prosper F; Hematology and Cell Therapy Department, Clinica Universidad de Navarra, IdiSNA, Pamplona, Spain.; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain.; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain.; Rodriguez-Madoz JR; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain.; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain.
Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Academic Journal
Rodriguez-Marquez P; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Calleja-Cervantes ME; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Computational Biology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Serrano G; Computational Biology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Oliver-Caldes A; Department of Hematology, Hospital Clinic de Barcelona, IDIBAPS, Universidad de Barcelona, Barcelona, Spain.; Palacios-Berraquero ML; Hematology and Cell Therapy Department, Clínica Universidad de Navarra (CUN), Pamplona, Spain.; Martin-Mallo A; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Calviño C; Hematology and Cell Therapy Department, Clínica Universidad de Navarra (CUN), Pamplona, Spain.; Español-Rego M; Department of Immunology, Hospital Clinic de Barcelona, IDIBAPS, Universidad de Barcelona, Barcelona, Spain.; Ceballos C; Hematology Service, Hospital Universitario de Navarra, IdiSNA, Pamplona, Spain.; Lozano T; Immunology and Immunotherapy Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; San Martin-Uriz P; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Vilas-Zornoza A; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Rodriguez-Diaz S; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Martinez-Turrillas R; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Jauregui P; Hematology and Cell Therapy Department, Clínica Universidad de Navarra (CUN), Pamplona, Spain.; Alignani D; Flow Cytometry Core, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Viguria MC; Hematology Service, Hospital Universitario de Navarra, IdiSNA, Pamplona, Spain.; Redondo M; Hematology Service, Hospital Universitario de Navarra, IdiSNA, Pamplona, Spain.; Pascal M; Department of Immunology, Hospital Clinic de Barcelona, IDIBAPS, Universidad de Barcelona, Barcelona, Spain.; Martin-Antonio B; Department of Hematology, Hospital Clinic de Barcelona, IDIBAPS, Universidad de Barcelona, Barcelona, Spain.; Juan M; Department of Immunology, Hospital Clinic de Barcelona, IDIBAPS, Universidad de Barcelona, Barcelona, Spain.; Immunotherapy platform Hospital Sant Joan de Déu, Barcelona, Spain.; Urbano-Ispizua A; Department of Hematology, Hospital Clinic de Barcelona, IDIBAPS, Universidad de Barcelona, Barcelona, Spain.; Rodriguez-Otero P; Hematology and Cell Therapy Department, Clínica Universidad de Navarra (CUN), Pamplona, Spain.; Alfonso-Pierola A; Hematology and Cell Therapy Department, Clínica Universidad de Navarra (CUN), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Paiva B; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Flow Cytometry Core, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Lasarte JJ; Immunology and Immunotherapy Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Inoges S; Hematology and Cell Therapy Department, Clínica Universidad de Navarra (CUN), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Immunology and Immunotherapy Department, Clínica Universidad de Navarra (CUN), Pamplona, Spain.; Lopez-Diaz de Cerio A; Hematology and Cell Therapy Department, Clínica Universidad de Navarra (CUN), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Immunology and Immunotherapy Department, Clínica Universidad de Navarra (CUN), Pamplona, Spain.; San-Miguel J; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Hematology and Cell Therapy Department, Clínica Universidad de Navarra (CUN), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Cancer Center Universidad de Navarra (CCUN), Pamplona, Spain.; Fernandez de Larrea C; Department of Hematology, Hospital Clinic de Barcelona, IDIBAPS, Universidad de Barcelona, Barcelona, Spain.; Hernaez M; Computational Biology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Data Science and Artificial Intelligence Institute (DATAI), Universidad de Navarra, Pamplona, Spain.; Rodriguez-Madoz JR; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Prosper F; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.; Hematology and Cell Therapy Department, Clínica Universidad de Navarra (CUN), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Cancer Center Universidad de Navarra (CCUN), Pamplona, Spain.
Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101653440 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2375-2548 (Electronic) Linking ISSN: 23752548 NLM ISO Abbreviation: Sci Adv Subsets: PubMed not MEDLINE; MEDLINE
Academic Journal
Peng J; Department of Electrical and Computer Engineering, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.; Serrano G; Computational Biology Program, CIMA University of Navarra, IdiSNA, Pamplona, Spain.; Traniello IM; Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.; Neuroscience Program, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.; Calleja-Cervantes ME; Computational Biology Program, CIMA University of Navarra, IdiSNA, Pamplona, Spain.; Hemato-Oncology Program, CIMA University of Navarra, IdiSNA, Pamplona, Spain.; Chembazhi UV; Department of Biochemistry, University of Illinois at Urbana, Urbana, IL, 61801, USA.; Bangru S; Department of Biochemistry, University of Illinois at Urbana, Urbana, IL, 61801, USA.; Ezponda T; Hemato-Oncology Program, CIMA University of Navarra, IdiSNA, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Madrid, Spain.; Rodriguez-Madoz JR; Hemato-Oncology Program, CIMA University of Navarra, IdiSNA, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Madrid, Spain.; Kalsotra A; Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.; Department of Biochemistry, University of Illinois at Urbana, Urbana, IL, 61801, USA.; Cancer Center@Illinois, Urbana, IL, 61801, USA.; Prosper F; Hemato-Oncology Program, CIMA University of Navarra, IdiSNA, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Madrid, Spain.; Hematology and Cell Therapy, Clinica Universidad de Navarra, Pamplona, Spain.; Ochoa I; Department of Electrical and Computer Engineering, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA. idoia@illinois.edu.; Department of Electrical Engineering (TECNUN), University of Navarra, San Sebastian, Spain. idoia@illinois.edu.; Data Science and Artificial Intelligence Institute (DATAI), Universidad de Navarra, Pamplona, Spain. idoia@illinois.edu.; Hernaez M; Computational Biology Program, CIMA University of Navarra, IdiSNA, Pamplona, Spain. mhernaez@unav.es.; Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA. mhernaez@unav.es.; Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Madrid, Spain. mhernaez@unav.es.; Data Science and Artificial Intelligence Institute (DATAI), Universidad de Navarra, Pamplona, Spain. mhernaez@unav.es.
Publisher: Nature Publishing Group UK Country of Publication: England NLM ID: 101719179 Publication Model: Electronic Cited Medium: Internet ISSN: 2399-3642 (Electronic) Linking ISSN: 23993642 NLM ISO Abbreviation: Commun Biol Subsets: MEDLINE
Academic Journal
Martinez-Turrillas R; Regenerative Medicine Program, CIMA Universidad de Navarra, 31008 Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; Martin-Mallo A; Hemato-Oncology Program, CIMA Universidad de Navarra, 31008 Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; Rodriguez-Diaz S; Regenerative Medicine Program, CIMA Universidad de Navarra, 31008 Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; Zapata-Linares N; Regenerative Medicine Program, CIMA Universidad de Navarra, 31008 Pamplona, Spain.; Rodriguez-Marquez P; Hemato-Oncology Program, CIMA Universidad de Navarra, 31008 Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; San Martin-Uriz P; Hemato-Oncology Program, CIMA Universidad de Navarra, 31008 Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; Vilas-Zornoza A; Hemato-Oncology Program, CIMA Universidad de Navarra, 31008 Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.; Calleja-Cervantes ME; Hemato-Oncology Program, CIMA Universidad de Navarra, 31008 Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; Salido E; Pathology Department, Hospital Universitario Canarias, Universidad La Laguna, 38320 Tenerife, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain.; Prosper F; Regenerative Medicine Program, CIMA Universidad de Navarra, 31008 Pamplona, Spain.; Hemato-Oncology Program, CIMA Universidad de Navarra, 31008 Pamplona, Spain.; Cell Therapy Area, Clinica Universidad de Navarra (CUN), 31008 Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.; Rodriguez-Madoz JR; Regenerative Medicine Program, CIMA Universidad de Navarra, 31008 Pamplona, Spain.; Hemato-Oncology Program, CIMA Universidad de Navarra, 31008 Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.
Publisher: Cell Press Country of Publication: United States NLM ID: 101624857 Publication Model: eCollection Cited Medium: Print ISSN: 2329-0501 (Print) Linking ISSN: 23290501 NLM ISO Abbreviation: Mol Ther Methods Clin Dev Subsets: PubMed not MEDLINE
Academic Journal
Rosselló-Tortella M; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute, 08916, Badalona, Barcelona, Catalonia, Spain.; Germans Trias i Pujol Health Science Research Institute, 08916, Badalona, Barcelona, Catalonia, Spain.; Llinàs-Arias P; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute, 08916, Badalona, Barcelona, Catalonia, Spain.; Sakaguchi Y; Department of Chemistry and Biotechnology, Graduate School of Engineering, University of Tokyo, 113-8656 Tokyo, Japan.; Miyauchi K; Department of Chemistry and Biotechnology, Graduate School of Engineering, University of Tokyo, 113-8656 Tokyo, Japan.; Davalos V; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute, 08916, Badalona, Barcelona, Catalonia, Spain.; Setien F; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute, 08916, Badalona, Barcelona, Catalonia, Spain.; Calleja-Cervantes ME; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute, 08916, Badalona, Barcelona, Catalonia, Spain.; Piñeyro D; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute, 08916, Badalona, Barcelona, Catalonia, Spain.; Centro de Investigacion Biomedica en Red Cancer, 28029 Madrid, Spain.; Martínez-Gómez J; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute, 08916, Badalona, Barcelona, Catalonia, Spain.; Guil S; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute, 08916, Badalona, Barcelona, Catalonia, Spain.; Germans Trias i Pujol Health Science Research Institute, 08916, Badalona, Barcelona, Catalonia, Spain.; Joshi R; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute, 08916, Badalona, Barcelona, Catalonia, Spain.; Villanueva A; Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, 08908, L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.; Suzuki T; Department of Chemistry and Biotechnology, Graduate School of Engineering, University of Tokyo, 113-8656 Tokyo, Japan.; Esteller M; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute, 08916, Badalona, Barcelona, Catalonia, Spain; mesteller@carrerasresearch.org.; Centro de Investigacion Biomedica en Red Cancer, 28029 Madrid, Spain.; Institucio Catalana de Recerca i Estudis Avançats, 08010 Barcelona, Catalonia, Spain.; Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona, 08907 Barcelona, Catalonia, Spain.
Publisher: National Academy of Sciences Country of Publication: United States NLM ID: 7505876 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1091-6490 (Electronic) Linking ISSN: 00278424 NLM ISO Abbreviation: Proc Natl Acad Sci U S A Subsets: MEDLINE
Academic Journal
Janin M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.; Ortiz-Barahona V; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.; de Moura MC; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.; Martínez-Cardús A; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.; Llinàs-Arias P; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.; Soler M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.; Nachmani D; Department of Medicine and Pathology, Cancer Research Institute, Beth Israel Deaconess Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Pelletier J; Molecular Mechanisms and Experimental Therapy in Oncology Program, Metabolism and Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.; Schumann U; EMBL-Australia Collaborating Group, Department of Genome Sciences, The John Curtin School of Medical Research, The Australian National University, Garran Road, Acton, ACT, 2601, Australia.; Calleja-Cervantes ME; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.; Moran S; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.; Guil S; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.; Bueno-Costa A; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.; Piñeyro D; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.; Perez-Salvia M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.; Rosselló-Tortella M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.; Piqué L; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.; Bech-Serra JJ; Proteomics Unit, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.; De La Torre C; Proteomics Unit, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.; Vidal A; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain.; Martínez-Iniesta M; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.; Martín-Tejera JF; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.; Villanueva A; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.; Arias A; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.; Cuartas I; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.; Aransay AM; Centro de Investigación Bimédica en Red de Enfermedades hepáticas y Digestivas (CIBERehd), CIC bioGUNE, 801A Bizkaia Technology Park, 48160, Derio, Spain.; La Madrid AM; Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Catalonia, Spain.; Pediatric Neuro-Oncology Unit, Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Catalonia, Spain.; Carcaboso AM; Preclinical Therapeutics and Drug Delivery Research Program, Fundacio Sant Joan de Deu, Barcelona, Catalonia, Spain.; Santa-Maria V; Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Catalonia, Spain.; Pediatric Neuro-Oncology Unit, Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Catalonia, Spain.; Mora J; Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Catalonia, Spain.; Fernandez AF; Institute of Oncology of Asturias (IUOPA), Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), 33011, Oviedo, Spain.; Fraga MF; Nanomaterials and Nanotechnology Research Center (CINN-CSIC), Universidad de Oviedo-Principado de Asturias, Oviedo, Spain.; Aldecoa I; Pathology-Brain Bank, Hospital Clínic de Barcelona-CDB-August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Catalonia, Spain.; Pedrosa L; Glioma and Neural Stem Cell Group and Translational Genomics and Targeted Therapeutics in Solid Tumors Team, IDIBAPS, Barcelona, Catalonia, Spain.; Graus F; Clinical and Experimental Neuroimmunology, IDIBAPS, Barcelona, Catalonia, Spain.; Vidal N; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.; Martínez-Soler F; Faculty of Medicine and Health Sciences-Bellvitge, Universitat de Barcelona, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.; Tortosa A; Faculty of Medicine and Health Sciences-Bellvitge, Universitat de Barcelona, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.; Carrato C; Department of Pathology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain.; Balañá C; Catalan Institute of Oncology, Hospital Germans Trias i Pujol, 08916, Badalona, Barcelona, Catalonia, Spain.; Boudreau MW; Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.; Hergenrother PJ; Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.; Kötter P; Institute for Molecular Biosciences, Goethe University, Frankfurt, Germany.; Entian KD; Institute for Molecular Biosciences, Goethe University, Frankfurt, Germany.; Hench J; Division of Neuropathology, Institute of Medical Genetics and Pathology, University Hospital Basel, 4031, Basel, Switzerland.; Frank S; Division of Neuropathology, Institute of Medical Genetics and Pathology, University Hospital Basel, 4031, Basel, Switzerland.; Mansouri S; Division of Neurosurgery, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada.; Zadeh G; Division of Neurosurgery, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada.; Dans PD; Joint IRB-BSC Program on Computational Biology, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), 08028, Barcelona, Catalonia, Spain.; Orozco M; Joint IRB-BSC Program on Computational Biology, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), 08028, Barcelona, Catalonia, Spain.; Department of Biochemistry and Biomedicine, University of Barcelona, 08028, Barcelona, Spain.; Thomas G; Molecular Mechanisms and Experimental Therapy in Oncology Program, Metabolism and Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.; Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Catalonia, Spain.; Division of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati Medical School, Cincinnati, OH, 45267-0508, USA.; Blanco S; CIC bioGUNE, 801A Bizkaia Technology Park, 48160, Derio, Spain.; Molecular Mechanisms Program, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC), University of Salamanca, 37007, Salamanca, Spain.; Seoane J; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.; Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain.; Preiss T; EMBL-Australia Collaborating Group, Department of Genome Sciences, The John Curtin School of Medical Research, The Australian National University, Garran Road, Acton, ACT, 2601, Australia.; Victor Chang Cardiac Research Institute, Darlinghurst (Sydney), NSW, 2010, Australia.; Pandolfi PP; Department of Medicine and Pathology, Cancer Research Institute, Beth Israel Deaconess Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Esteller M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain. mesteller@carrerasresearch.org.; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain. mesteller@carrerasresearch.org.; Department of Biochemistry and Biomedicine, University of Barcelona, 08028, Barcelona, Spain. mesteller@carrerasresearch.org.; Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain. mesteller@carrerasresearch.org.; Josep Carreras Leukaemia Research Institute (IJC), Ctra de Can Ruti, Camí de les Escoles s/n, 08916, Badalona, Barcelona, Catalonia, Spain. mesteller@carrerasresearch.org.
Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0412041 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0533 (Electronic) Linking ISSN: 00016322 NLM ISO Abbreviation: Acta Neuropathol Subsets: MEDLINE
Academic Journal
Gómez-Miragaya J; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.; Morán S; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.; Calleja-Cervantes ME; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.; Collado-Sole A; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.; Paré L; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Gómez A; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.; Serra V; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Dobrolecki LE; Departments of Molecular and Cellular Biology and Radiology, The Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Lewis MT; Departments of Molecular and Cellular Biology and Radiology, The Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Diaz-Lagares A; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.; Cancer Epigenomics, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), CIBERONC, Santiago de Compostela, Spain.; Eroles P; Biomedical Research Institute (INCLIVA), Valencia, Spain. CIBERONC, Spain.; Prat A; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Esteller M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.; Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Spain.; Josep Carreras Leukaemia Research Institute, Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.; González-Suárez E; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. egsuarez@idibell.cat.
Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101150042 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3125 (Electronic) Linking ISSN: 15417786 NLM ISO Abbreviation: Mol Cancer Res Subsets: MEDLINE
Academic Journal
Oliveira-Mateos C; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.; Sánchez-Castillo A; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Carlos III Institute of Health (ISCIII), Madrid, Spain.; Soler M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.; Obiols-Guardia A; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.; Piñeyro D; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.; Boque-Sastre R; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.; Cardiff School of Biosciences, Cardiff University, Museum Avenue, Cardiff, CF10 3AX, Wales, UK.; Calleja-Cervantes ME; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.; Castro de Moura M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.; Martínez-Cardús A; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.; Rubio T; Laboratory of Cancer Metabolism, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.; Pelletier J; Laboratory of Cancer Metabolism, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.; Martínez-Iniesta M; Program Against Cancer Therapeutic Resistance (ProCURE), ICO, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.; Herrero-Martín D; Sarcoma Research Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.; Tirado OM; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Carlos III Institute of Health (ISCIII), Madrid, Spain.; Sarcoma Research Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.; Gentilella A; Laboratory of Cancer Metabolism, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.; Department of Biochemistry and Physiology, Faculty of Pharmacy, University of Barcelona (UB), Barcelona, Catalonia, Spain.; Villanueva A; Program Against Cancer Therapeutic Resistance (ProCURE), ICO, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.; Esteller M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Carlos III Institute of Health (ISCIII), Madrid, Spain.; Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Catalonia, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain.; Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain.; Farré L; Program Against Cancer Therapeutic Resistance (ProCURE), ICO, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain. mfarre@idibell.cat.; Laboratory of Experimental Pathology (LAPEX), Gonçalo Moniz Research Center, Oswaldo Cruz Foundation (CPQGM/FIOCRUZ), Salvador, Bahia, Brazil. mfarre@idibell.cat.; Guil S; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain. sguil@carrerasresearch.org.; Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain. sguil@carrerasresearch.org.
Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Academic Journal
Llinàs-Arias P; Cancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain.; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain.; Rosselló-Tortella M; Cancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain.; López-Serra P; Cancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain.; Pérez-Salvia M; Cancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain.; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain.; Setién F; Cancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain.; Marin S; Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, University of Barcelona, Barcelona, Spain.; Institute of Biomedicine of Universitat de Barcelona (IBUB), Barcelona, Spain.; CIBER of Liver and Digestive Diseases (CIBEREHD), Madrid, Spain.; Muñoz JP; Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, University of Barcelona, Barcelona, Spain.; Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona, Spain.; CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), Madrid, Spain.; Junza A; CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), Madrid, Spain.; Metabolomics Platform, IISPV, Department of Electronic Engineering (DEEEA), Universitat Rovira i Virgili, Tarragona, Catalonia, Spain.; Capellades J; CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), Madrid, Spain.; Metabolomics Platform, IISPV, Department of Electronic Engineering (DEEEA), Universitat Rovira i Virgili, Tarragona, Catalonia, Spain.; Calleja-Cervantes ME; Cancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain.; Ferreira HJ; Cancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain.; de Moura MC; Cancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain.; Srbic M; Cancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain.; Martínez-Cardús A; Cancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain.; de la Torre C; Proteomics Unit, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.; Villanueva A; Translational Research Laboratory, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.; Cascante M; Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, University of Barcelona, Barcelona, Spain.; Institute of Biomedicine of Universitat de Barcelona (IBUB), Barcelona, Spain.; CIBER of Liver and Digestive Diseases (CIBEREHD), Madrid, Spain.; Yanes O; CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), Madrid, Spain.; Metabolomics Platform, IISPV, Department of Electronic Engineering (DEEEA), Universitat Rovira i Virgili, Tarragona, Catalonia, Spain.; Zorzano A; Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, University of Barcelona, Barcelona, Spain.; Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona, Spain.; CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), Madrid, Spain.; Moutinho C; Cancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain.; CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.; Esteller M; Cancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain.; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain.; Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain.; Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona, Catalonia, Spain.
Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: Electronic Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE
검색 결과 제한하기
제한된 항목
[Author] Calleja-Cervantes ME
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어